Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
The combination demonstrated durable survival benefits among patients with metastatic non–small cell lung cancer (mNSCLC) regardless of PD-L1 expression levels at a minimum follow-up of more than 6 years.
Neoadjuvant treatment with the combination of nivolumab and ipilimumab led to responses and was well tolerated in patients with resectable hepatocellular carcinoma.